Company intelligence / Profile preview

Pep2Tango Therapeutics

Potomac, Maryland, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~15
Development stage: Preclinical

Overview

Pep2Tango’s lead program is a first-in-class unimolecular tetra-receptor agonist peptide for obesity. Preclinical studies have shown superior weight loss compared to tirzepatide, with selective fat mass loss, muscle mass preservation, improved lipid profiles, better glycemic control, and beneficial liver effects. The company is preparing for IND submission in 2025 and has not yet entered clinical trials.[3][6]

Therapeutic areas: EndocrinologyCardiovascularNeurologyMetabolic Disorders
Modalities: Synthetic peptidesUnimolecular multi-receptor peptide agonists[1][3][4]
Industry: Biotech

Drug pipeline

1 asset

PTT-A

Preclinical

Partnerships

Versant Ventures (lead investor/backer)[8]

Beyond the preview

Go deeper on Pep2Tango Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pep2Tango Therapeutics.

Explore the full profile